Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223 dichloride

- PMLiVE

AstraZeneca picks location for global HQ and research base

Decides on the Cambridge Biomedical Campus in UK

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

- PMLiVE

AstraZeneca boosts R&D prospects with Pearl acquisition

Deal to acquire respiratory firm could be worth up to $1.15bn

- PMLiVE

FDA gives priority review status to BMS/ AZ’s metreleptin

Former obesity prospect has potential in the rare disease lipodystrophy

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

- PMLiVE

Eylea set to challenge Lucentis in UK after NICE recommendation

Bayer’s medicine recommended for NHS use to treat wet AMD

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

AstraZeneca offers $443m to buy Omthera

Adds to list of deals to boost flagging pipeline

- PMLiVE

Bayer wins EU approval for Xarelto in ACS

Comes despite US FDA decision not to recommend extra indication for anticoagulant

- PMLiVE

New chief information officer at Bayer Healthcare

Promotion for Johannes Schubmehl

- PMLiVE

France ignores EMA and suspends Bayer’s Diane 35

National Agency for the Safety of Drugs and Health Products contradicts PRAC verdict

- PMLiVE

India puts cost controls on medicines

Drugs (Prices Control) Order 2013 reduces price of hundreds of drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links